Shandong Sinobioway Biomedicine News

Unnamed Medicine: Notice on matters involving litigation

May 5 12:00 ET

Unnamed Pharmaceuticals: Announcement on Stock Price Changes and Risk Alerts

Apr 29 12:00 ET

Unnamed Pharmaceuticals: Notice on Convening the 2024 Annual General Meeting of Shareholders

Apr 28 12:00 ET

Unnamed Pharmaceuticals: Announcement on the Disqualification of the Holding Subsidiary from Interprovincial Alliance Procurement Selection

Apr 28 12:00 ET

Unnamed Pharmaceuticals: Announcement on Board Election for a New Term

Apr 28 12:00 ET

Unnamed Pharmaceuticals: Announcement on Suspension of Production, Sales and Risk Alerts by Holding Subsidiaries

Apr 24 12:00 ET

Shandong Sinobioway Biomedicine: Regarding the evaluation report on the performance of accounting firms in 2024 and the report on the fulfillment of supervisory responsibilities by the audit committee.

Apr 23 12:00 ET

Shandong Sinobioway Biomedicine: 2024 Financial Year-End Settlement Report.

Apr 23 12:00 ET

Shandong Sinobioway Biomedicine: Announcement on the provision for asset impairment for the year 2024.

Apr 23 12:00 ET

Shandong Sinobioway Biomedicine: Internal Control Rules Implementation Self-Inspection Form for 2024.

Apr 23 12:00 ET

Shandong Sinobioway Biomedicine: Summary table of non-operating fund occupation and Other related fund transactions for the year 2024.

Apr 23 12:00 ET

Shandong Sinobioway Biomedicine: Announcement regarding the increase of capital in the wholly-owned subsidiary and the amendment of the articles of association of the wholly-owned subsidiary.

Apr 23 12:00 ET

Shandong Sinobioway Biomedicine: Announcement regarding the use of idle self-owned funds to purchase financial products.

Apr 23 12:00 ET

Shandong Sinobioway Biomedicine: Explanation from the Board of Directors' Audit Committee on the reasonableness of the provision for asset impairment in 2024.

Apr 23 12:00 ET

Unnamed Pharmaceuticals: Announcement on the Intent to Sign a “Sales Contract”

Mar 12 12:00 ET

Unnamed Medicine: Announcement on the intention to sign the “General Contracting Contract for Construction Projects”

Jan 23 11:00 ET

Unnamed Medicine: Announcement on the Proposed Signing of the “Technical Service Agreement for Drug Clinical Trials”

Jan 3 11:00 ET

Unnamed Pharmaceuticals: Announcement on capital increase to wholly-owned subsidiary

Jan 3 11:00 ET

Unnamed Pharmaceuticals: Announcement of Resolutions of the 2024 Fourth Extraordinary General Meeting of Shareholders

Dec 18, 2024 11:00 ET

Unnamed Medicine: Legal Opinion of Zhejiang Tianze (Shenzhen) Law Firm on the 2024 Fourth Extraordinary General Meeting of Shareholders of Unnamed Medicine

Dec 18, 2024 11:00 ET